Literature DB >> 3463441

Mediterranean diet and primary IgA nephropathy.

R Coppo, B Basolo, C Rollino, D Roccatello, G Martina, A Amore, G Bongiorno, G Piccoli.   

Abstract

Since IgA nephropathy can be experimentally induced by alimentary antigens, mechanisms of oral immunization might be supposed also in human primary IgA nephropathy (PIgAGN). IgA immune complexes (IgAIC) are thought to play a major role in PIgAGN, hence this parameter was monitored in six PIgAGN patients subjected to diets excluding gluten, meat or eggs respectively and selected as having persistent urinary activity and high IgAIC levels. On gluten-free diet IgAIC significantly decreased over 3 different periods of 10 days (Student's t-test p 1 less than 0.03, Rank-Signed test p 2 less than 0.02), 1 month (p 1 less than 0.007, p 2 less than 0.02) and 6 months (p 1 less than 0.05, p 2 less than 0.02). IgAIC significantly increased again on a gluten containing diet over 1 month (p 1 less than 0.008, p 2 less than 0.04) and 3 months (p 1 less than 0.02, p 2 less than 0.04). After 6 months on a gluten-free diet, all patients had normal IgAIC values and decreased IgA2 subclass-IgAIC, in agreement with the hypothesis of withdrawal of an antigen challenging the mucosal immune system. These data indicate a relationship between a gluten-containing diet and high levels of IgAIC in PIgAGN patients, suggesting that dietetic factors might play a role in the different geographical distribution of this nephropathy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3463441

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  18 in total

Review 1.  The rheumatic poison: a survey of some published investigations of the immunopathogenesis of Henoch-Schönlein purpura.

Authors:  J F Knight
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

2.  IgA-containing immune complexes after challenge with food antigens in patients with IgA nephropathy.

Authors:  S Jackson; Z Moldoveanu; K A Kirk; B A Julian; T F Patterson; A L Mullins; T Jilling; J Mestecky; J H Galla
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

Review 3.  Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II).

Authors:  L K Golightly; S S Smolinske; M L Bennett; E W Sutherland; B H Rumack
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

4.  Glomerular deposition of food antigens in IgA nephropathy.

Authors:  M Sato; H Kojima; K Takayama; S Koshikawa
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

5.  Presence of shared idiotypes in serum and immune complexes in patients with IgA nephropathy.

Authors:  J González-Cabrero; J Egido; J Sancho; F Moldenhauer
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

6.  Do IgA antigliadin and IgA antiendomysium antibodies show there is latent coeliac disease in primary IgA nephropathy?

Authors:  C Sategna-Guidetti; G Ferfoglia; M Bruno; R Pulitano; D Roccatello; A Amore; R Coppo
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

7.  IgA nephropathy presenting clinicopathological features of acute post-streptococcal glomerulonephritis.

Authors:  K Okada; S Saitoh; Z Sakaguchi; R J Zhang; T Kuhara; K Yasutomo; Y Kuroda
Journal:  Eur J Pediatr       Date:  1996-04       Impact factor: 3.183

8.  Effects of neutral pepsin on the deposition of dietary antigens in glomeruli from IgA nephropathy.

Authors:  M Sato; H Kojima; K Kino; S Koshikawa
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

Review 9.  Treatment of IgA nephropathy.

Authors:  C Y Lin
Journal:  Springer Semin Immunopathol       Date:  1994

10.  Characterization of circulating idiotypes containing immune complexes and their presence in the glomerular mesangium in patients with IgA nephropathy.

Authors:  J González-Cabrero; J Egido; F Mampaso; M C Rivas; L Hernando
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.